Physician profile
Peter D Bloom
NPI 1316923253
$7,577.90
in general payments reported to CMS, 2019-2025
35 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $308 · 2021: $76.78 · 2022: $1,466 · 2023: $1,765 · 2024: $1,598 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,780 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,779.98 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,753.78 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,031.70 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.33 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $309.59 | 2022-2025 | |
| Qol Medical, LLC | $286.26 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $279.66 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $263.31 | 2019-2025 | |
| Ardelyx, INC. | $245.88 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $218.81 | 2024-2025 | Voquezna |
| Celgene Corporation | $200.68 | 2022-2023 | Zeposia |
| Cook Medical LLC | $150.33 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $143.72 | 2019-2025 | Rebyota |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Braintree Laboratories, INC. | $121.67 | 2019-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $112.31 | 2020-2025 | Ocaliva |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $105.58 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $92.37 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $89.33 | 2023-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $86.94 | 2019-2024 | Dificid |
| Amgen INC. | $78.56 | 2022-2023 | Amjevita, Avsola |
| Organon LLC | $58.59 | 2023-2025 | Renflexis, Hadlima |
| Ucb, INC. | $51.95 | 2019-2020 | |
| Allergan, INC. | $40.07 | 2019-2020 | |
| Daiichi Sankyo INC. | $38.18 | 2019-2022 | |
| Sandoz INC. | $30.97 | 2024-2025 | Pyzchiva, Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $27.36 | 2025 | Iqirvo |
| Orphalan INC | $23.57 | 2024 | Cuvrior |
| Madrigal Pharmaceuticals | $22.84 | 2024 | Resmetirom |
| Nestle Healthcare Nutrition INC. | $22.28 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.96 | 2023 | Cyltezo |
| Exact Sciences Corporation | $20.60 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $20.58 | 2025 | Wegovy |
| Celltrion USA INC. | $17.36 | 2025 | Vegzelma |
| Endo Pharmaceuticals INC. | $11.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.